Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Lixte Biotechnology stock
Learn how to easily invest in Lixte Biotechnology stock.
Lixte Biotechnology Holdings Inc is a biotechnology business based in the US. Lixte Biotechnology shares (LIXT) are listed on the NASDAQ and all prices are listed in US Dollars. Lixte Biotechnology employs 3 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Lixte Biotechnology
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – LIXT – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Lixte Biotechnology stock price (NASDAQ: LIXT)Use our graph to track the performance of LIXT stocks over time.
Lixte Biotechnology shares at a glance
|Latest market close||$0.75|
|52-week range||$0.66 - $4.12|
|50-day moving average||$1.01|
|200-day moving average||$1.51|
|Wall St. target price||N/A|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-0.49|
Buy Lixte Biotechnology shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Lixte Biotechnology stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Lixte Biotechnology price performance over time
|1 week (2022-06-22)||-2.08%|
|1 month (2022-05-27)||-0.79%|
|3 months (2022-03-30)||-38.70%|
|6 months (2021-12-30)||-34.43%|
|1 year (2021-06-30)||-75.12%|
|2 years (2020-06-26)||N/A|
|3 years (2019-06-28)||1|
|5 years (2017-06-29)||523.14%|
Lixte Biotechnology financials
|Gross profit TTM||$0|
|Return on assets TTM||-69.22%|
|Return on equity TTM||-119.74%|
|Market capitalisation||$13.4 million|
TTM: trailing 12 months
Lixte Biotechnology share dividends
We're not expecting Lixte Biotechnology to pay a dividend over the next 12 months.
You may also wish to consider:
- Amgen (AMGN.US) (3.25% forward annual dividend yield)
- BioNTech (BNTX.US) (1.33% forward annual dividend yield)
Have Lixte Biotechnology's shares ever split?
Lixte Biotechnology's shares were split on a 1:6 basis on 19 November 2020. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Lixte Biotechnology shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Lixte Biotechnology shares which in turn could have impacted Lixte Biotechnology's share price.
Lixte Biotechnology share price volatility
Over the last 12 months, Lixte Biotechnology's shares have ranged in value from as little as $0.66 up to $4.12. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lixte Biotechnology's is -1.1724. This would suggest that Lixte Biotechnology's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Lixte Biotechnology has bucked the trend.
To put Lixte Biotechnology's beta into context you can compare it against those of similar companies.
Lixte Biotechnology overview
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc. ; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute.
Lixte Biotechnology in the news
LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF BAS VAN DER BAAN, INTERNATIONALLY RECOGNIZED BIOTECH BUSINESS DEVELOPMENT EXECUTIVE, TO ITS BOARD OF DIRECTORS
LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF PROFESSOR RENÉ BERNARDS TO ITS BOARD OF DIRECTORS
Frequently asked questionsWhat percentage of Lixte Biotechnology is owned by insiders or institutions?
Currently 55.608% of Lixte Biotechnology shares are held by insiders and 7.272% by institutions. How many people work for Lixte Biotechnology?
Latest data suggests 3 work at Lixte Biotechnology. When does the fiscal year end for Lixte Biotechnology?
Lixte Biotechnology's fiscal year ends in December. Where is Lixte Biotechnology based?
Lixte Biotechnology's address is: 680 East Colorado Boulevard, Pasadena, CA, United States, 91101 What is Lixte Biotechnology's ISIN number?
Lixte Biotechnology's international securities identification number is: US5393192027
More guides on Finder
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
How to buy Warrantee (WRNT) stock when it goes public
Everything we know about the Warrantee IPO, plus information on how to buy in.
How to buy Treasure Global (TGL) stock when it goes public
Everything we know about the Treasure Global IPO, plus information on how to buy in.
How to buy BIOLIFE4D (SAVU) stock when it goes public
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
Ask an Expert